Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

HMI 115 is being discussed as a potential hair loss treatment, with skepticism due to past disappointments like cosmeRNA, brezula, and pyrilutamide. The user is questioning if they should be hopeful for new developments in the next six years.

Switching from topical Minoxidil and oral Finasteride to Him's 3-in-1 oral pill containing Minoxidil, Finasteride, and vitamins. Users discuss experiencing shedding after the switch, with hopes for improved hair growth.

The conversation is about a user offering free unused Eucapil after switching to finasteride for hair loss treatment. The user did not use Eucapil and is willing to give it away locally or ship it if costs are covered.

Verteporfin followed by retinoic acid improves wound regeneration in mini-pigs. Retinoic acid does not significantly enhance regeneration in rabbits.

Capilia Longa and Scandinavian Biolabs are discussed, with skepticism about their effectiveness and value. The conversation suggests avoiding these products due to high cost and perceived lack of results.

The user is seeking a substitute for Tretinoin to enhance the effectiveness of Minoxidil for hair loss. They are considering using Retinol as an alternative.

RU58841 is used to eliminate scalp itch. Users discuss difficulty finding reliable and affordable sources.

Eucapil, containing fluridil, is used for hair loss but has impractical packaging. Some users find it effective for maintenance, while others suggest alternatives like anageninc with pyrilutamide.

Breezula is expected to launch in late 2026, with data being sent to the FDA in early 2026. The process is typical for a successful trial.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

The conversation discusses Kintor's initiation of a new Phase 3 trial to assess the long-term safety of Pyrilutamide (KX-826) for hair loss, which will last 52 weeks. Specific treatments mentioned include Pyrilutamide.

OP developed hives after using Kx 826 (Pyrilutamide) 1% twice daily for 3 weeks. The hives appeared on the arms, chest, and groin area.

PP405 is a medicine, and Google Ventures is funding its development based on evidence from each phase, unlike their investment in Juicero, which was a trend-based gamble. Investing in medicine is a calculated risk, not reliant on being "cool."

The user is considering using 2 vials of Fluridil every other day instead of 1 vial daily for better scalp coverage. They are questioning if this method would be as effective.

Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.

Dr. Toyos is recruiting more participants for a larger trial on hair loss treatments. The discussion mentions Minoxidil, finasteride, and RU58841 as potential treatments.

Amplifica is developing new molecules for hair growth, with clinical trials expected soon, while Engraft Technologies is improving FUE robotic technology to make hair transplants faster and cheaper. Users express interest in the timeline for AMP-303 and concerns about high costs and effectiveness of current treatments.

A user is considering a hair transplant for density and is unsure whether to choose Reviva or Darling Buds, with Reviva being cheaper. Another user advises against Reviva due to poor experiences and suggests considering medication for hair density instead.

RepliCel has purchased Trichoscience, and they have a video about hair multiplication. The conversation also mentions treatments like Minoxidil, finasteride, and RU58841.

The user switched from Hims topical finasteride and minoxidil to Musely Hair Pill Bloom+, which includes minoxidil, dutasteride, and other vitamins, and noticed new hair growth but also experienced lower blood pressure. Another user ordered a minoxidil-only pill.

Veradermics is working on FDA approval for extended-release oral Minoxidil. Approval is expected around 2027.

Rejuv-3X, a topical blend with GHK-Cu, AHK-Cu, and JXL-089, is used for hair loss, offering a targeted option without finasteride's side effects. The user plans to combine it with microneedling for enhanced results.

The conversation discusses hair regrowth progress using Minoxidil, finasteride, and RU58841. It highlights the transformation of vellus hairs into terminal hairs in a Norwood 6 frontal area.

The conversation discusses using PGE2 as a hair growth stimulant, comparing it to minoxidil, and considering the addition of Setipiprant. Concerns about side effects like skin damage and cost are also mentioned.

Breezula's effectiveness may depend on the vehicle used for its application, with concerns about the grey market version's formulation. Phase 3 results are promising, but skepticism remains about the grey market product's authenticity and effectiveness.

A user is concerned that prolonged use of valisone (betamethasone) and clotrimazole solution for scalp dermatitis may be causing hair thinning and loss. They noticed thinning in the area where the solution was applied.

The conversation is about finding a cheaper source for RU58841, with a suggestion to use Chemyo. One user suggests that RU58841 may not be necessary.

Yunce Medical, a Chinese company, is developing hair multiplication technology similar to Stemson Therapeutics, with potential for quicker availability due to favorable regulations. Users express skepticism and hope for future advancements in hair loss treatments.

Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.

The user reports significant hair regrowth using a topical solution of 5% minoxidil and 0.1% finasteride twice daily, along with derma rolling twice a week. They have not experienced shedding and are optimistic about continued hair growth.